Assay validation in acute coronary syndrome
Allan S. Jaffe, M.D., leads this project with the goal of developing new tests for the detection of myocardial injury in patients with intermediate or lower risk of an acute coronary syndrome (ACS).
It is estimated that over 8 million people with ACS visit emergency departments yearly, but only 15 to 20 percent have cardiovascular disease. Cardiac troponin has been established to assist the diagnosis, treatment and basis for risk stratification in patients with acute myocardial infarction. However, recent literature advocates the use of a variety of new markers to increase the rapidity of diagnosis, as well as aid in defining pathophysiological subsets and improving risk stratification. Thus, the team is collecting blood samples on patients with ACS or suspected ACS to have a repository for validating and developing new tests for detection of myocardial injury.